SYNAPS Dx Resolves Alzheimer’s Disease Diagnostic Dilemma: White Paper Documents Improved Diagnostic Pathway with Highly Accurate, Accessible Skin Test
“With the introduction of newly approved drugs to treat AD such as lecanemab, there is growing need to accurately identify the appropriate patients for prescribing these drugs, given their cost and risk/benefit profiles,” says Frederick Huie, M.D., medical director, CVS/Aetna and SYNAPS Dx advisory council member.